NVS Jan 2026 65.000 put

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

0.9500

0.0000

(0.00%)

As of 12:00PM EDT. Market open.

Thomson Reuters StreetEvents
Q1 2024 Legend Biotech Corp Earnings Call
Q1 2024 Legend Biotech Corp Earnings Call
GlobeNewswire
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for
The Telegraph
Questor: this medical stock is expensive – but worth paying for
It’s a stock market rule of thumb that big acquisitions tend to destroy shareholder value. Spin-offs, on the other hand, have the reassuring habit of being more likely to create it.